PE20090996A1 - Derivados de pirrolopirimidina como inhibidores de cinasa jak3 - Google Patents
Derivados de pirrolopirimidina como inhibidores de cinasa jak3Info
- Publication number
- PE20090996A1 PE20090996A1 PE2008000586A PE2008000586A PE20090996A1 PE 20090996 A1 PE20090996 A1 PE 20090996A1 PE 2008000586 A PE2008000586 A PE 2008000586A PE 2008000586 A PE2008000586 A PE 2008000586A PE 20090996 A1 PE20090996 A1 PE 20090996A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrimidine
- amino
- members
- pirrolo
- phenyl
- Prior art date
Links
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 3-AMINOSULFONYLPHENYL Chemical class 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 abstract 1
- YVVMIGRXQRPSIY-UHFFFAOYSA-N 7-deaza-2-aminopurine Chemical compound N1C(N)=NC=C2C=CN=C21 YVVMIGRXQRPSIY-UHFFFAOYSA-N 0.000 abstract 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07380088 | 2007-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090996A1 true PE20090996A1 (es) | 2009-07-15 |
Family
ID=38475914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000586A PE20090996A1 (es) | 2007-04-02 | 2008-03-31 | Derivados de pirrolopirimidina como inhibidores de cinasa jak3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110160185A9 (enExample) |
| EP (1) | EP2142550A1 (enExample) |
| JP (1) | JP2010523522A (enExample) |
| KR (1) | KR20100015353A (enExample) |
| CN (1) | CN101679440A (enExample) |
| AR (1) | AR065901A1 (enExample) |
| AU (1) | AU2008234822A1 (enExample) |
| BR (1) | BRPI0809992A2 (enExample) |
| CA (1) | CA2682646A1 (enExample) |
| CL (1) | CL2008000946A1 (enExample) |
| IL (1) | IL201073A0 (enExample) |
| MX (1) | MX2009010595A (enExample) |
| PE (1) | PE20090996A1 (enExample) |
| RU (1) | RU2009140319A (enExample) |
| TW (1) | TW200904442A (enExample) |
| WO (1) | WO2008119792A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| PT2323993E (pt) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8258144B2 (en) * | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| TW201024298A (en) * | 2008-09-23 | 2010-07-01 | Palau Pharma Sa | (R)-3-(N,N-dimethylamino)pyrrolidine derivatives |
| EP2373653B1 (en) * | 2008-12-05 | 2014-04-02 | F. Hoffmann-La Roche AG | Pyrrolopyrazinyl urea kinase inhibitors |
| CA2764885C (en) * | 2009-06-08 | 2018-05-15 | Takeda Pharmaceutical Company Limited | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| BR112012010186B8 (pt) * | 2009-10-29 | 2021-05-25 | Palau Pharma Sa | derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos |
| US9586961B2 (en) | 2010-07-09 | 2017-03-07 | Leo Pharma A/S | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| EP2606051B1 (en) | 2010-08-20 | 2016-10-05 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| WO2012030912A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
| EP2611809A1 (en) * | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
| US8877760B2 (en) | 2011-11-23 | 2014-11-04 | Portola Pharmaceuticals, Inc. | Substituted pyrazine-2-carboxamide kinase inhibitors |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| US9745320B2 (en) | 2013-01-18 | 2017-08-29 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| US20170137426A1 (en) * | 2014-03-28 | 2017-05-18 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| NO2721710T3 (enExample) * | 2014-08-21 | 2018-03-31 | ||
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| US10913744B2 (en) | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
| CN104876934B (zh) * | 2015-05-12 | 2017-08-11 | 山东大学 | 一种含氮杂环苯基哌啶类化合物及其制备方法与应用 |
| PL3303348T3 (pl) * | 2015-05-28 | 2020-02-28 | Theravance Biopharma R&D Ip, Llc | Związki naftyrydyny jako inhibitory kinazy JAK |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CA3251507A1 (en) | 2015-10-16 | 2025-05-21 | Abbvie Inc | Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| CN110526915B (zh) * | 2018-05-25 | 2022-02-01 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂的制备方法 |
| MX2021005334A (es) * | 2018-11-05 | 2021-06-23 | Avista Pharma Solutions Inc | Compuestos quimicos. |
| US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3955920A1 (en) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| KR20200133188A (ko) * | 2019-05-17 | 2020-11-26 | 보로노이바이오 주식회사 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
| CN110183471B (zh) * | 2019-05-21 | 2022-02-15 | 江苏大学 | 一种哌嗪类衍生物及制备方法及应用 |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| IL303237A (en) * | 2020-11-27 | 2023-07-01 | Anrui Biomedical Tech Guangzhou Co Ltd | Aminoheteroaryl kinase inhibitors |
| WO2022117012A1 (zh) * | 2020-12-02 | 2022-06-09 | 百极弘烨（广东）医药科技有限公司 | 螺环jak抑制剂、含其的药物组合物及其应用 |
| KR102585193B1 (ko) * | 2021-04-08 | 2023-10-06 | 주식회사 스탠다임 | 신규한 lrrk2 억제제 |
| EP4526469A1 (en) | 2022-05-16 | 2025-03-26 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| AU2023298142A1 (en) * | 2022-06-29 | 2025-01-09 | Alcon Inc. | Azetidinyl pyrimidines and uses thereof as jak inhibitors |
| CN118005609B (zh) * | 2022-11-09 | 2025-06-17 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| RS50087B (sr) * | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
| JP5227032B2 (ja) * | 2005-02-03 | 2013-07-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なピロロピリミジン |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
-
2008
- 2008-03-31 KR KR1020097020666A patent/KR20100015353A/ko not_active Withdrawn
- 2008-03-31 AU AU2008234822A patent/AU2008234822A1/en not_active Abandoned
- 2008-03-31 CN CN200880015843A patent/CN101679440A/zh active Pending
- 2008-03-31 EP EP08735625A patent/EP2142550A1/en not_active Withdrawn
- 2008-03-31 BR BRPI0809992-8A2A patent/BRPI0809992A2/pt not_active IP Right Cessation
- 2008-03-31 AR ARP080101351A patent/AR065901A1/es not_active Application Discontinuation
- 2008-03-31 JP JP2010501495A patent/JP2010523522A/ja not_active Withdrawn
- 2008-03-31 CA CA002682646A patent/CA2682646A1/en not_active Abandoned
- 2008-03-31 RU RU2009140319/04A patent/RU2009140319A/ru not_active Application Discontinuation
- 2008-03-31 WO PCT/EP2008/053842 patent/WO2008119792A1/en not_active Ceased
- 2008-03-31 US US12/594,228 patent/US20110160185A9/en not_active Abandoned
- 2008-03-31 MX MX2009010595A patent/MX2009010595A/es not_active Application Discontinuation
- 2008-03-31 PE PE2008000586A patent/PE20090996A1/es not_active Application Discontinuation
- 2008-04-01 TW TW097111869A patent/TW200904442A/zh unknown
- 2008-04-01 CL CL200800946A patent/CL2008000946A1/es unknown
-
2009
- 2009-09-21 IL IL201073A patent/IL201073A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010523522A (ja) | 2010-07-15 |
| KR20100015353A (ko) | 2010-02-12 |
| AR065901A1 (es) | 2009-07-08 |
| EP2142550A1 (en) | 2010-01-13 |
| AU2008234822A1 (en) | 2008-10-09 |
| CA2682646A1 (en) | 2008-10-09 |
| WO2008119792A1 (en) | 2008-10-09 |
| TW200904442A (en) | 2009-02-01 |
| CN101679440A (zh) | 2010-03-24 |
| MX2009010595A (es) | 2009-10-22 |
| BRPI0809992A2 (pt) | 2014-10-14 |
| RU2009140319A (ru) | 2011-05-10 |
| IL201073A0 (en) | 2010-05-17 |
| US20100113420A1 (en) | 2010-05-06 |
| CL2008000946A1 (es) | 2008-10-10 |
| US20110160185A9 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090996A1 (es) | Derivados de pirrolopirimidina como inhibidores de cinasa jak3 | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| TNSN06411A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| SMT201300098B (it) | Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide | |
| MX2009011276A (es) | Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad. | |
| EA201070164A1 (ru) | Твердый препарат, включающий алоглиптин и гидрохлорид метформина | |
| EA201001017A1 (ru) | 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы | |
| MX2009011964A (es) | Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico. | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| JO3007B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
| CL2009001152A1 (es) | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. | |
| PE20090887A1 (es) | DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6 | |
| UA116768C2 (uk) | Дизаміщені бензотієнілпіролотриазини та їх застосування як інгібіторів кінази рфрф | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| PE20141686A1 (es) | Compuestos de piperazina alquilados como inhibidores de actividad btk | |
| NO20082496L (no) | Pyrazinderivater | |
| DK1791830T3 (da) | Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer | |
| EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| TW200612936A (en) | Indole derivatives | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| NI200700189A (es) | Ciclopropil -(2,3-dimetilbencil)amidos del ácido 7-{4-[2-(2,6-dicloro-4-metilfenoxi)- etoxi]fenil}-3,9- diazabiciclo [3.3.1]non-6-en-6-carboxílico como inhibidores de renina para el tratamiento de la hipertensión. | |
| WO2008126901A1 (ja) | 含窒素複素環化合物およびそれを含有する医薬組成物 | |
| MX2009011059A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
| MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |